Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/GLP-1

GLP-1

6

Pipeline Programs↗

9

Active Trials↗

4

Companies Involved↗

GLP-1 is an early-stage landscape with 6 programs across 4 companies.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

22/100

Mech. Concentration

100/100

Completion Rate

88/100

Attrition Rate

9/100

Pipeline

Programs by Phase

Preclinical4

Dipeptidyl Peptidase 4 Inhibitor

Boehringer Ingelheim

GLP-1

Rigshospitalet, Denmark

Colesevelam

Cosette Pharmaceuticals, Inc.

Chenodeoxycholic Acid

Leadiant Biosciences, Inc.

Phase 11

Acute Ethanol Dose

University of Wisconsin, Madison

Phase 21

Semaglutide

Novo Nordisk

Phase 3

No programs

Approved

No programs

Analysis

Modality Breakdown

75%

Small molecule

3 of 4 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 83% of 6 pipeline programs.

Analysis

Trial Status

47

clinical trials

Completed28 · 60%

Unknown status6 · 13%

Recruiting5 · 11%

Terminated4 · 9%

Not yet recruiting3 · 6%

Active, not recruiting1 · 2%

Clinical Trials

Trial Activity

47 trials

Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy: A Randomized Controlled Trial.

Recruiting·FFu Jen Catholic University Hospital·Phase 3·NCT07736911·140 enrolled

Discontinuation Recommendations for GLP-1 Receptor Agonists Prior to Colonoscopy: A Randomized Controlled Trial in Taiwan.

Recruiting·FFu Jen Catholic University Hospital·Preclinical·NCT07736963·240 enrolled

Lifestyle Change Implementation Research Network at PRC at UMass Chan

Recruiting·UUniversity of Massachusetts, Worcester·Preclinical·NCT07481305·220 enrolled

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

Recruiting·—·N/A·NCT07309094·250 enrolled

GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

Recruiting·—·Phase 2·NCT05356104·110 enrolled

GLP-1s to Enhance Lasting Optimal Weight

Active, not recruiting·WWake Forest University Health Sciences·Phase 4·NCT06861439·40 enrolled

Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics

Not yet recruiting·UUniversity of Wisconsin, Madison·Phase 1·NCT07758231·5 enrolled

Impact of GLP-1 Receptor Agonists on Patients With IPMN

Not yet recruiting·HHôpital Fribourgeois·N/A·NCT07014709·30 enrolled

GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV

Not yet recruiting·VVanderbilt University Medical Center·Phase 2·NCT07221214·200 enrolled

The Effect of GLP-1 on the Inhibition of Glucagon Secretion

Completed·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT01507597·30 enrolled

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01967589·82 enrolled

GLP-1 Medicines and Mental Health Changes

Completed·UUniversity of California, San Diego·N/A·NCT07368855·90 enrolled

The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 Secretion

Completed·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT03018444·15 enrolled

Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion

Completed·—·Phase 1·NCT02749032·24 enrolled

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Completed·UUniversity of Washington·Phase 4·NCT01524705·102 enrolled

Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)